 WAKEFIELD, Mass., May 27, 2021 GLOBE NEWSWIRE -- Innovation Pharmaceuticals OTCQB:IPIX the Company, a clinical stage biopharmaceutical company, today announces that patient enrollment in the Companys 120-patient, Phase 2 clinical trial of Brilacidin for COVID-19 has reached 90 percent and that the Company anticipates full enrollment to be completed in approximately two weeks. 